Aktive Überwachung und Krebs-Follow-up

Some cancers and pre-cancerous conditions are safely monitored before any treatment is given. This is called active surveillance or watchful waiting, and it is a recognised, evidence-based strategy for conditions such as low-risk prostate cancer, very small thyroid cancers, some slow lymphomas and chronic lymphocytic leukaemia, and small kidney tumours. Treatment starts only if tests show the disease is changing.

This service also covers follow-up after treatment has finished, to detect recurrence and manage late effects. In both settings the aim is to avoid treating people who do not need it while not missing the moment when treatment matters. Monitoring reduces but cannot remove the chance that disease progresses between checks.

Bedingungen, die dieser Service betreut

• Low-risk and some favourable intermediate-risk prostate cancer
• Papillary thyroid microcarcinoma
• Small kidney masses, especially in older people
• Indolent lymphomas and early chronic lymphocytic leukaemia
• Low-grade conditions such as Barrett's oesophagus, MGUS and some ductal carcinoma in situ within trials
• Follow-up after treatment for breast, bowel, lung, head and neck and other cancers
• Rectal cancer with a complete response to chemoradiotherapy, under a watch and wait protocol

Tests, die Ihnen möglicherweise angeboten werden

• Scheduled blood tests: PSA, thyroglobulin, CEA, blood counts or other markers at set intervals.
• Repeat imaging: Ultrasound, MRI, CT or PET-CT, compared directly with earlier scans.
• Repeat biopsy or endoscopy: For example a repeat prostate biopsy guided by MRI, or colonoscopy after bowel cancer.
• Clinical examination and symptom review: New symptoms between visits should always be reported.
• Survivorship assessment: Heart, bone, hormone and psychological checks for late effects of earlier treatment.

Behandlungen verfügbar

• Continued surveillance: For as long as the agreed criteria remain stable, which for many people means years or for life.
• Definitive treatment on progression: Surgery, radiotherapy or drug treatment, offered when the grade, size or markers cross defined thresholds. For most surveillance candidates, delayed treatment does not appear to worsen long-term outcomes.
• Treatment by patient choice: Some people find living with untreated cancer too stressful and opt for treatment, which is a legitimate decision.
• Treatment of recurrence: Planned by a tumour board according to where and when the cancer has returned.
• Management of late effects and rehabilitation: Lymphoedema, fatigue, hormonal changes, fertility and return to work.

Wann Sie eine Fachmeinung einholen sollten

• You have been offered surveillance and want a second opinion on whether it is safe for you
• Your PSA, scan or biopsy has changed and you are unsure whether it is time to treat
• You were advised to have immediate surgery for a low-risk cancer and want to know whether monitoring is an option
• You have finished treatment and have no clear follow-up plan
• New or persistent symptoms after cancer treatment

Reisen nach Türkiye für diese Pflege

Surveillance depends on the same tests being repeated at regular intervals and compared over years, so it must be anchored with a doctor where you live. A visit can offer a second opinion on whether to continue monitoring or move to treatment, a high-quality MRI or PET-CT, a targeted biopsy, or the planned treatment itself once the decision has been made. Bring all earlier results and the actual scan images, not just the reports, so that changes can be measured accurately.

Senden Sie Ihre Berichte, Scans und eine kurze Geschichte und eine Clinic-Y Koordinator Antworten innerhalb von 24 Stunden mit geeigneten Teams und schriftlich, All-inclusive Vorschläge nebeneinander. Die Überprüfung Ihres Falls ist kostenlos.

Häufig gestellte Fragen